<?xml version="1.0" encoding="UTF-8"?>
<ref id="cts12816-bib-0004">
 <label>4</label>
 <mixed-citation publication-type="miscellaneous" id="cts12816-cit-0004">
  <collab collab-type="authors">US Food and Drug Administration (FDA)</collab> . 
  <article-title>Recommendations for Investigational COVID‐19 Convalescent Plasma</article-title>. &lt;
  <ext-link ext-link-type="uri" xlink:href="https://www.fda.gov/vaccines-blood-biologics/investigational-new-drug-ind-or-device-exemption-ide-process-cber/recommendations-investigational-covid-19-convalescent-plasma" xmlns:xlink="http://www.w3.org/1999/xlink">https://www.fda.gov/vaccines‐blood‐biologics/investigational‐new‐drug‐ind‐or‐device‐exemption‐ide‐process‐cber/recommendations‐investigational‐covid‐19‐convalescent‐plasma</ext-link>&gt; (
  <year>2020</year>). Accessed April 30, 2020.
 </mixed-citation>
</ref>
